Nuvaring Related Published Studies
Well-designed clinical trials related to Nuvaring (Etonogestrel / Ethinyl Estradiol Vaginal Ring)
A randomized controlled trial of NuvaRing versus combined oral contraceptive pills for pretreatment in in vitro fertilization cycles. [2011.09]
Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. [2005.03]
Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. [2005]
A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. [2004.09]
The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. [2004.03]
The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. [2004.02]
The combined contraceptive ring NuvaRing and spermicide co-medication. [2003.04]
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. [2001.05]
Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. [2000.09]
Well-designed clinical trials possibly related to Nuvaring (Etonogestrel / Ethinyl Estradiol Vaginal Ring)
Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. [2011.09.13]
Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. [2010.03]
Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. [2010.03]
Sexual function in first-time contraceptive ring and contraceptive patch users. [2010.01]
[Combined hormonal contraception in cycles artificially extended]. [2010.01]
Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. [2008.09]
Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. [2008.08]
Extended regimens of the contraceptive vaginal ring: a randomized trial. [2005.09]
Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. [2004.11]
Ovarian function with a novel combined contraceptive vaginal ring. [2002.10]
Other research related to Nuvaring (Etonogestrel / Ethinyl Estradiol Vaginal Ring)
Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women with type 1 diabetes mellitus. [2010.09]
Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle
control) of extended regimens of the vaginally inserted hormone-releasing system
'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women
with type 1 diabetes mellitus. [2010]
[Vaginal combined contraception NuvaRing in the clinical practice in the Czech Republic] [2009.08]
Review of the vaginal contraceptive ring (NuvaRing). [2008.10]
An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing. [2008.07]
Review of the combined contraceptive vaginal ring, NuvaRing. [2008.04]
Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany. [2008.03]
Use of the NuvaRing(R) hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus. [2008.02]
Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. [2007.09]
Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing(R): Results of clinical experience in Germany. [2007.08.28]
The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring. [2007.08]
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. [2006.12]
Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. [2006.09]
The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands. [2006.03]
Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. [2006.01]
The combined contraceptive vaginal ring (NuvaRing) and endometrial histology. [2005.11]
The combined contraceptive vaginal device (NuvaRing): a comprehensive review. [2005.06]
The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study. [2004.06]
The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study. [2004.05]
Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing. [2004]
The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. [2003.03]
High acceptability and satisfaction with NuvaRing use. [2002.12]
Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. [2002.12]
Complete and robust ovulation inhibition with NuvaRing. [2002.12]
In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. [2002.01.31]
Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. [2001.03]
Other possibly related research studies
Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. [2005.09]
Nondaily hormonal contraception: considerations in contraceptive choice and patient counseling. [2004.06]
Update on contraception: benefits and risks of the new formulations. [2003.08]
Steroidal contraceptive vaginal rings. [2003.06]
Lower hormone dosage with improved cycle control. [2002.12]
Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. [2002.03]
The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. [2005.10]
Vaginal rings for menopausal symptom relief. [2004]
New hormonal contraceptives: a comprehensive review of the literature. [2003.12]
Progress in contraception: new technology. [2003.07]
Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. [2002.09]
[New forms of hormonal contraception] [2000.05]
Ovarian activity and bleeding patterns during extended continuous use of a combined contraceptive vaginal ring. [1992.09]
Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. [1990.12]
Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol. [1990.11]
Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol. [1990.09]
A multi-compartment vaginal ring system for independently adjustable release of contraceptive steroids. [1986.12]
Comparing patient telephone callback rates for different hormonal birth control delivery systems. [2006.11]
Etanercept treatment of erythema nodosum. [2007.07]
Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. [2007.11]
Daily context matters: predictors of missed oral contraceptive pills among college and graduate students. [2010.10]
The contraceptive vaginal ring. [2010.03]
Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. [2010.02.19]
Accidental introduction of a contraceptive vaginal ring into the urinary bladder. [2009.12]
Combined contraceptive ring versus combined oral contraceptive (30-mug ethinylestradiol and 3-mg drospirenone). [2011.08]
Contraceptive vaginal rings: a review. [2010.11]
The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. [2010.05]
Contraceptive options for women in selected circumstances. [2010.10]
Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized
controlled trial with norethisterone. [2012]
Sexual function in first-time contraceptive ring and contraceptive patch users. [2010]
|
